A paper by David Ridley, Henry Grabowski, and Jeffrey Moe (Duke) proposes that the FDA create "priority voucher reviews" for pharmaceutical companies that introduce drugs fo neglected or tropical diseases, as an alternative to extended patent life.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment